 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H18N2O3 |
| Molar mass | 310.353 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2.[1] It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.
On December 23, 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger. As of 2008, Phase II was completed and Ligand.
Upon reviewing company website (Ligand.com) this drug is currently not listed at the moment due to several programs already partnered with GSK. GSK holds a significant share of the drug RLS drug programs on the market with Requip XR and the recent FDA approval of Horizant. To prevent any direct competition and losing strong ties with GSK, Aplindore is not listed at the moment on Lidgand website. If this medication were to reach phase III, this could adversely effect Ligand`s portfolio of partnered and unpartnered assets. By electing not to list the drug on company website, Ligand maintains the appearance that they are "currently actively seeking a partner" when a potential investor inquirers about drug development via email.
References
- ^ Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH (December 2006). "Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist". European Journal of Pharmacology. 552 (1–3): 36–45. doi:10.1016/j.ejphar.2006.08.063. PMID 17056032.
This page was last edited on 13 November 2022, at 20:14